New CBD & THC Cannabis Oils Now Shipping To Australia From Canada
New CBD & THC Cannabis Oils Now Shipping To Australia From Canada
MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) announced on Wednesday that Canadian-produced GMP Beacon Medical cannabis oil and inhalation cartridges have launched in the Australian medical marijuana market.
医疗药业实验室公司多伦多证券交易所股票代码：Labs)(场外交易代码：MEDIF)(多伦多证券交易所股票代码：MLZ)周三宣布，加拿大生产的GMP烽火医疗我大麻澳大利亚医用大麻市场已经推出了油盒和吸入盒。
The cannabis oil portfolio features a high CBD Isolate (THC-free) oil, a balanced oil and a THC dominant full spectrum oil made with Beacon's popular medical flower strains.
大麻油产品组合以高CBD分离(不含THC)油、平衡油和由Beacon广受欢迎的药用花卉品种制成的THC优势全光谱油为特色。
The inhalation cartridges include flavor-forward options popular with patients in the Canadian market and strain-specific full-spectrum cartridges that utilize flower varieties already favored by Beacon Medical patients.
这些吸入药盒包括在加拿大市场上广受患者欢迎的香料转发选项，以及使用Beacon Medical患者已经喜欢的花卉品种的菌株特定全光谱药盒。
With Beacon Medical's Pink Kush and GSC products available in flower, oil and inhalation formats, the company provides physicians and patients with three delivery methods to consume the same full spectrum strains.
Beacon Medical的粉色库什和GSC产品有花、油和吸入三种形式，该公司为医生和患者提供了三种给药方式，以消耗相同的全谱菌株。
Deliveries of inhalation cartridges to patients kicked off this week, and cannabis oils are scheduled to ship from Canada this week as well, the Toronto, Canada-based company said in a press release.
本周开始向患者交付吸入弹这家总部位于加拿大多伦多的公司在一份新闻稿中表示，大麻油也计划本周从加拿大发货。
MediPharm holds an Australian GMP license from the Therapeutic Goods Administration (TGA), complemented by its GMP status from Health Canada (Drug Establishment License) and the US FDA.
MediPharm拥有澳大利亚治疗药品管理局(TGA)颁发的GMP许可证，并获得加拿大卫生部(药品机构许可证)和美国FDA的GMP资格。
In July 2023, the TGA revised import and medical cannabis regulations, requiring all products to meet cGMP standards.
2023年7月，TGA修订了进口和医用大麻法规，要求所有产品都符合cGMP标准。
What's Next
接下来是什么？
Beacon Medical Australia plans to educate and collect feedback on these products from physicians and patients with the help of its recently expanded medical scientific liaison field team.
Beacon Medical Australia计划在其最近扩大的医疗科学联络领域团队的帮助下，教育和收集医生和患者对这些产品的反馈。
This allows MediPharm Labs further access to the Australian medical cannabis market.
这使得MediPharm Labs能够进一步进入澳大利亚医用大麻市场。
Want to watch our Cannabis Capital Conference live? For existing subscribers you can get direct access through our research platform. For new users, you can get instant access here!
想看我们的大麻之都大会现场直播吗？对于现有的订阅者，您可以直接访问通过我们的研究平台。对于新用户，您可以获得即时访问此处好了！
MEDIF Price Action
MEDIF价格行动
MediPharm's shares traded 0.2686% higher at $0.056 per share at the time of writing on Wednesday morning.
周三上午，在撰写本文时，医药集团的股价上涨了0.2686%，至每股0.056美元。
Related News
相关新闻
- MediPharm Labs Breaks Free From Royalty Agreement, What It Means & What's Next
- Could Medical Cannabis Be The Answer For Fibromyalgia? Here's What New Study Found
- Cannabinoid-Focused Pharma Stock Slides On Q2 Earnings Report, Here Are The Details
- MediPharm Delivers Cannabis Clinical Trial Material To US Research Partner And Provides Update On FDA Status
- 医药实验室打破版税协议，意味着什么&下一步是什么
- 医用大麻是治疗纤维肌痛的良药吗？以下是新研究的发现
- 专注于大麻类药物的制药股第二季度收益报告幻灯片，以下是详细信息
- MediPharm向美国研究合作伙伴提供大麻临床试验材料并提供FDA最新情况
Photo: Courtesy of Kimzy Nanney on Unsplash
图片：由Kimzy Nanney在UnSplash上提供